Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (65)

« Back to Publications

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil

Costa Clemens SA. et al, (2025), Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 9, 100642 - 100642

Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222)

Belij-Rammerstorfer S. et al, (2025), eBioMedicine, 118, 105847 - 105847

Rift Valley fever seroprevalence and risk factors among human populations in Uganda’s cattle corridor: a cross-sectional study

Anywaine Z. et al, (2025), BMJ Public Health, 3, e002563 - e002563

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials

Venkatraman N. et al, (2025), The Lancet Microbe, 6, 100868 - 100868

Adenoviral vaccines—Infectious disease

Bliss CM. et al, (2025), 573 - 642

Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial

Satti I. et al, (2024), The Lancet Infectious Diseases, 24, 909 - 921

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse

Flaxman A. et al, (2024), PLOS Pathogens, 20, e1012262 - e1012262

Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates

Peralta Alvarez MP. et al, (2024), Frontiers in Immunology, 15

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.

Hamaluba M. et al, (2023), Wellcome open research, 8

Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination

Bitencourt J. et al, (2022), Frontiers in Immunology, 12

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations

Berg A. et al, (2021), Vaccines, 9, 1249 - 1249

Load More

1
2
3
4
5